Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

被引：0
|
作者：
Roe, MT [1 ]
Sapp, SK [1 ]
Lincoff, AM [1 ]
机构：
[1] Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA
来源：
CLEVELAND CLINIC JOURNAL OF MEDICINE | 2000年 / 67卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Glycoprotein (GP) IIb/IIIa inhibitors are potent antiplatelet agents and represent an exciting breakthrough in the treatment of acute coronary syndromes. However, their safety and cost-effectiveness require further investigation, and more information on risk stratification is needed to clarify which patients benefit the most from empiric use of these agents.
引用
收藏
页码：131 / 140
页数：12
相关论文
共 50 条
  • [31] Roundtable panel discussion: The role of glycoprotein IIb-IIIa receptor inhibitors in acute ischemic coronary syndromes
    White, HD
    Tcheng, JE
    Harrington, RA
    Phillips, D
    Kleiman, NS
    AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (4A): : B44 - B48
  • [32] Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes
    Dabbous, O. H.
    Anderson, F. A., Jr.
    Gore, J. M.
    Eagle, K. A.
    Fox, K. A. A.
    Mehta, R. H.
    Goldberg, R. J.
    Agnelli, G.
    Steg, P. G.
    HEART, 2008, 94 (02) : 159 - 165
  • [33] Low molecular weight heparins combined with platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes
    Salam, AM
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (09) : 1567 - 1570
  • [34] Glycoprotein IIb/IIIa receptor inhibitors in percutaneous coronary intervention and acute coronary syndrome
    Crouch, MA
    Nappi, JM
    Cheang, KI
    ANNALS OF PHARMACOTHERAPY, 2003, 37 (06) : 860 - 875
  • [35] Analysis of number needed to treat and cost of platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary interventions and acute coronary syndromes
    Bell, DM
    PHARMACOTHERAPY, 1999, 19 (09): : 1086 - 1093
  • [36] Platelet glycoprotein IIb/IIIa-receptor inhibitors in patients with acute coronary syndromes or undergoing percutaneous coronary interventions: A review
    Truong, KM
    Amankwa, K
    Kucukarslan, S
    CLINICAL THERAPEUTICS, 2001, 23 (08) : 1145 - 1165
  • [37] Safety and effectiveness of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the SPUM-ACS study
    Bruno, F.
    Wenzl, F.
    De Filippo, O.
    Kraler, S.
    Giacobbe, F.
    Roffi, M.
    Muller, O.
    Raber, L.
    Templin, C.
    De Ferrari, G. M.
    D'ascenzo, F.
    Luescher, T. F.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [38] Safety and effectiveness of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the SPUM-ACS study
    Bruno, Francesco
    Wenzl, Florian A.
    De Filippo, Ovidio
    Kraler, Simon
    Giacobbe, Federico
    Roffi, Marco
    Muller, Olivier
    Raber, Lorenz
    Templin, Christian
    De Ferrari, Gaetano Maria
    D'Ascenzo, Fabrizio
    Luscher, Thomas F.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2024, 10 (05) : 391 - 402
  • [39] Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors
    Freeman, RV
    Mehta, RH
    Al Badr, W
    Cooper, JV
    Kline-Rogers, E
    Eagle, KA
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (05) : 718 - 724
  • [40] Impact of glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes without ST-elevation in the "real world"
    Monteiro, P
    EUROPEAN HEART JOURNAL, 2004, 25 : 86 - 87
12345